- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04964934
Исследование фазы III для оценки ингибитора AZD9833+ CDK4/6 при HR+/HER2-MBC с определяемой СОЭ1m до прогрессирования (SERENA-6) (SERENA-6)
Фаза III, двойное слепое, рандомизированное исследование для оценки перехода на AZD9833 (следующее поколение, пероральный SERD) + ингибитор CDK4/6 (палбоциклиб или абемациклиб) по сравнению с постоянным ингибитором ароматазы (летрозол или анастрозол) + ингибитор CDK4/6 в HR+/ Пациенты с HER2-MBC с обнаруживаемой мутацией ESR1 без прогрессирования заболевания во время лечения 1 л ингибитором ароматазы + ингибитором CDK4/6 - исследование раннего переключения под контролем цтДНК
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Breast cancer is the most common type of cancer among women. In people with breast cancer, the body is not able to control the growth of some cells. These extra cells can form tumors in the breast. When tumor cells move to different parts of the body this is called advanced cancer. Researchers are looking for better ways to treat advanced breast cancer.
This trial will look at six drugs: palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and AZD9833. AZD9833 is the trial drug, and is the only drug not yet approved for use. Palbociclib, abemaciclib and ribociclib work in the same way and are a type of cancer drug called a CDK4/6 inhibitor. Letrozole and anastrozole work in the same way and are both a type of cancer drug called an aromatase inhibitor (AI). CDK4/6 inhibitors and AIs work together to block the tumor's ability to grow. These drugs have been approved for combined use in people with advanced breast cancer that is HR-positive and HER2-negative. But if people get mutations in the ESR1 gene, it can make the AI and CDK4/6 inhibitor treatment work less well.
The trial drug, AZD9833, is designed to work with a CDK4/6 inhibitor in the same way that an AI does. Researchers think that AZD9833 might work better with a CDK4/6 inhibitor than an AI does in people who get mutations in their ESR1 gene.
Participants in this trial will have already been receiving one of the following combinations of a CDK4/6 inhibitor and an AI:
- palbociclib + anastrozole
- palbociclib + letrozole
- abemaciclib + anastrozole
- abemaciclib + letrozole
- ribociclib + anastrozole
- ribociclib + letrozole
During the trial, participants will remain on the same CDK4/6 inhibitor that they were taking before the trial.
In this trial, the researchers want to find out how well switching a participant with an ESR1 gene mutation from an AI (letrozole or anastrozole) to AZD9833 works in the treatment of advanced breast cancer that is HR-positive and HER2-negative.
The researchers will look at which trial treatment helps the participants live longer with the cancer before it gets worse.
The researchers also want to know more about how safe AZD9833 is.
The trial participants will be split into 2 groups:
- Participants in Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo
- Participants in Group B will receive an AI, a CDK4/6 inhibitor, and a placebo
A placebo looks like a treatment but does not have any medicine in it.
A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.
The participants will take their trial treatments over 28-day cycles, with a placebo and either AZD9833 or an AI taken once daily by mouth for all 28 days. If the participant is taking abemaciclib, they will take it twice daily by mouth for all 28 days. If the participant is taking palbociclib or ribociclib, they will take it once daily by mouth for 21 days and then stop taking it for the final 7 days of the cycle. The participant will then repeat the 28-day cycle receiving the trial treatment in the same way for as long as they are in the trial.
Participants will visit their trial site regularly throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.
Participants will take their trial treatment until their cancer gets worse or they decide to leave the trial.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
-
Birtinya, Австралия, 4575
- Research Site
-
Darlinghurst, Австралия, 2010
- Research Site
-
-
-
-
-
Graz, Австрия, 8036
- Research Site
-
Innsbruck, Австрия, 6020
- Research Site
-
Salzburg, Австрия, 5020
- Research Site
-
Vienna, Австрия, 1130
- Research Site
-
-
-
-
-
Leuven, Бельгия, 3000
- Research Site
-
Liège, Бельгия, 4000
- Research Site
-
Namur, Бельгия, 5000
- Research Site
-
-
-
-
-
Haskovo, Болгария, 6300
- Research Site
-
Panagyurishte, Болгария, 4500
- Research Site
-
Pleven, Болгария, 5804
- Research Site
-
Plovdiv, Болгария, 4004
- Research Site
-
Sofia, Болгария, 1431
- Research Site
-
Sofia, Болгария, 1407
- Research Site
-
Sofia, Болгария, 1527
- Research Site
-
Sofia, Болгария, 1330
- Research Site
-
Sofia, Болгария, 1303
- Research Site
-
-
-
-
-
Budapest, Венгрия, 1122
- Research Site
-
Budapest, Венгрия, 1062
- Research Site
-
Miskolc, Венгрия, 3526
- Research Site
-
Szekszárd, Венгрия, 7100
- Research Site
-
Szolnok, Венгрия, 5000
- Research Site
-
Zalaegerszeg, Венгрия, 8900
- Research Site
-
-
-
-
-
Ansbach, Германия, 91522
- Research Site
-
Augsburg, Германия, 86156
- Research Site
-
Bonn, Германия, 53111
- Research Site
-
Chemnitz, Германия, 09116
- Research Site
-
Dresden, Германия, 01307
- Research Site
-
Erlangen, Германия, 91054
- Research Site
-
Essen, Германия, 45130
- Research Site
-
Freiburg im Breisgau, Германия, 79110
- Research Site
-
Hösbach, Германия, 63768
- Research Site
-
Immenstadt im Allgäu, Германия, 87509
- Research Site
-
Koblenz, Германия, 56068
- Research Site
-
Leipzig, Германия, 4103
- Research Site
-
Mannheim, Германия, 68167
- Research Site
-
München, Германия, 80634
- Research Site
-
Paderborn, Германия, 33098
- Research Site
-
Ratingen, Германия, 40878
- Research Site
-
Ravensburg, Германия, 88212
- Research Site
-
Regensburg, Германия, 93053
- Research Site
-
Stade, Германия, 21680
- Research Site
-
Tübingen, Германия, 72076
- Research Site
-
Ulm, Германия, 89075
- Research Site
-
-
-
-
-
Beersheba, Израиль, 8410101
- Research Site
-
Haifa, Израиль, 3109601
- Research Site
-
Jerusalem, Израиль, 91120
- Research Site
-
Petah Tikva, Израиль, 494142
- Research Site
-
Ramat Gan, Израиль, 5262000
- Research Site
-
-
-
-
-
A Coruña, Испания, 15009
- Research Site
-
Badalona, Испания, 08003
- Research Site
-
Barcelona, Испания, 8035
- Research Site
-
L'Hospitalet de Llobregat, Испания, 08908
- Research Site
-
Madrid, Испания, 28041
- Research Site
-
Madrid, Испания, 28040
- Research Site
-
Murcia, Испания, 30008
- Research Site
-
Málaga, Испания, 29010
- Research Site
-
Sant Joan Despí, Испания, 08970
- Research Site
-
Seville, Испания, 41013
- Research Site
-
Valencia, Испания, 46010
- Research Site
-
-
-
-
-
Bergamo, Италия, 24127
- Research Site
-
Bologna, Италия, 40138
- Research Site
-
Florence, Италия, 50134
- Research Site
-
Meldola, Италия, 47014
- Research Site
-
Milan, Италия, 20141
- Research Site
-
Milan, Италия, 20132
- Research Site
-
Misterbianco, Италия, 95045
- Research Site
-
Naples, Италия, 80131
- Research Site
-
Padova, Италия, 35128
- Research Site
-
Roma, Италия, 00168
- Research Site
-
Rozzano, Италия, 20089
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Канада, T2N 5G2
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Канада, V5Z 4E6
- Research Site
-
-
Ontario
-
Ottawa, Ontario, Канада, K1H 8L6
- Research Site
-
-
Quebec
-
Lévis, Quebec, Канада, G6V 3Z1
- Research Site
-
Montreal, Quebec, Канада, H2X 0C1
- Research Site
-
Montreal, Quebec, Канада, H3T 1E2
- Research Site
-
Montreal, Quebec, Канада, H1T 2M4
- Research Site
-
Québec, Quebec, Канада, G1S 4L8
- Research Site
-
-
-
-
-
Drammen, Норвегия, 3004
- Research Site
-
Oslo, Норвегия, 0450
- Research Site
-
-
-
-
-
Bydgoszcz, Польша, 85-796
- Research Site
-
Gdynia, Польша, 81-519
- Research Site
-
Koszalin, Польша, 75-581
- Research Site
-
Lodz, Польша, 90-302
- Research Site
-
Poznan, Польша, 60-693
- Research Site
-
Rzeszów, Польша, 35-001
- Research Site
-
Tomaszów Mazowiecki, Польша, 97-200
- Research Site
-
Warsaw, Польша, 02-781
- Research Site
-
-
-
-
-
Guimarães, Португалия, 4835-044
- Research Site
-
Lisbon, Португалия, 1649-035
- Research Site
-
Lisbon, Португалия, 1400-038
- Research Site
-
Lisbon, Португалия, 1500-650
- Research Site
-
Lisbon, Португалия, 1449-005
- Research Site
-
Loures, Португалия, 2674-514
- Research Site
-
Porto, Португалия, 4099-001
- Research Site
-
Porto, Португалия, 4200-319
- Research Site
-
Porto, Португалия, 4200-072
- Research Site
-
Vila Nova de Gaia, Португалия, 4434-502
- Research Site
-
-
-
-
-
Moscow, Россия, 111123
- Research Site
-
Moscow, Россия, 143423
- Research Site
-
Moscow, Россия, 129090
- Research Site
-
Nizhny Novgorod, Россия, 603126
- Research Site
-
Podolsk, Россия, 142100
- Research Site
-
Saint Petersburg, Россия, 197758
- Research Site
-
Saint Petersburg, Россия, 194017
- Research Site
-
-
-
-
-
Banská Bystrica, Словакия, 974 01
- Research Site
-
Bratislava, Словакия, 833 01
- Research Site
-
Košice, Словакия, 041 91
- Research Site
-
Michalovce, Словакия, 07101
- Research Site
-
Partizánske, Словакия, 958 01
- Research Site
-
-
-
-
-
Blackpool, Соединенное Королевство, FY3 8NR
- Research Site
-
Cambridge, Соединенное Королевство, CB2 0QQ
- Research Site
-
London, Соединенное Королевство, SW3 6JJ
- Research Site
-
London, Соединенное Королевство, WC1N 3BG
- Research Site
-
Manchester, Соединенное Королевство, M20 4BX
- Research Site
-
Newport, Соединенное Королевство, NP10 8FZ
- Research Site
-
Nottingham, Соединенное Королевство, NG5 1PB
- Research Site
-
Portsmouth, Соединенное Королевство, PO6 3LY
- Research Site
-
Reading, Соединенное Королевство, RG2 9LH
- Research Site
-
Sheffield, Соединенное Королевство, S10 2SJ
- Research Site
-
Sutton, Соединенное Королевство, SM2 5PT
- Research Site
-
Taunton, Соединенное Королевство, TA1 5DA
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85054
- Research Site
-
-
Arkansas
-
Hot Springs, Arkansas, Соединенные Штаты, 71913
- Research Site
-
Little Rock, Arkansas, Соединенные Штаты, 72205
- Research Site
-
-
California
-
Long Beach, California, Соединенные Штаты, 90806
- Research Site
-
San Diego, California, Соединенные Штаты, 92123
- Research Site
-
Santa Rosa, California, Соединенные Штаты, 92805
- Research Site
-
-
Colorado
-
Grand Junction, Colorado, Соединенные Штаты, 81501
- Research Site
-
Lone Tree, Colorado, Соединенные Штаты, 80124
- Research Site
-
-
Florida
-
Fort Myers, Florida, Соединенные Штаты, 33901
- Research Site
-
Jacksonville, Florida, Соединенные Штаты, 32256
- Research Site
-
Jacksonville, Florida, Соединенные Штаты, 32224
- Research Site
-
St. Petersburg, Florida, Соединенные Штаты, 33705
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30318
- Research Site
-
Atlanta, Georgia, Соединенные Штаты, 30322
- Research Site
-
Atlanta, Georgia, Соединенные Штаты, 30342
- Research Site
-
-
Illinois
-
Park Ridge, Illinois, Соединенные Штаты, 60068
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, Соединенные Штаты, 46804
- Research Site
-
Indianapolis, Indiana, Соединенные Штаты, 46250
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21202
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Research Site
-
Fairhaven, Massachusetts, Соединенные Штаты, 02719
- Research Site
-
Foxborough, Massachusetts, Соединенные Штаты, 02035
- Research Site
-
Milford, Massachusetts, Соединенные Штаты, 01757
- Research Site
-
South Weymouth, Massachusetts, Соединенные Штаты, 02190
- Research Site
-
-
Michigan
-
Detroit, Michigan, Соединенные Штаты, 48202
- Research Site
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Соединенные Штаты, 55905
- Research Site
-
-
Mississippi
-
Oxford, Mississippi, Соединенные Штаты, 38655
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Соединенные Штаты, 64111
- Research Site
-
St Louis, Missouri, Соединенные Штаты, 63110
- Research Site
-
-
Montana
-
Billings, Montana, Соединенные Штаты, 59101
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68130
- Research Site
-
-
New Jersey
-
Camden, New Jersey, Соединенные Штаты, 08103
- Research Site
-
Ridgewood, New Jersey, Соединенные Штаты, 07450
- Research Site
-
-
New York
-
Brooklyn, New York, Соединенные Штаты, 11215
- Research Site
-
East Syracuse, New York, Соединенные Штаты, 13057
- Research Site
-
New Hyde Park, New York, Соединенные Штаты, 11042
- Research Site
-
New York, New York, Соединенные Штаты, 10065
- Research Site
-
New York, New York, Соединенные Штаты, 11355
- Research Site
-
Shirley, New York, Соединенные Штаты, 11967
- Research Site
-
-
North Carolina
-
Goldsboro, North Carolina, Соединенные Штаты, 27534
- Research Site
-
-
Ohio
-
Canton, Ohio, Соединенные Штаты, 44710
- Research Site
-
Cincinnati, Ohio, Соединенные Штаты, 45220
- Research Site
-
Columbus, Ohio, Соединенные Штаты, 43219
- Research Site
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97213
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- Research Site
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15213
- Research Site
-
York, Pennsylvania, Соединенные Штаты, 17403
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Соединенные Штаты, 29607
- Research Site
-
West Columbia, South Carolina, Соединенные Штаты, 29169
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Соединенные Штаты, 37916
- Research Site
-
Memphis, Tennessee, Соединенные Штаты, 38120
- Research Site
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Research Site
-
-
Texas
-
Bedford, Texas, Соединенные Штаты, 76022
- Research Site
-
Dallas, Texas, Соединенные Штаты, 75246
- Research Site
-
Houston, Texas, Соединенные Штаты, 77030
- Research Site
-
Houston, Texas, Соединенные Штаты, 77024
- Research Site
-
Longview, Texas, Соединенные Штаты, 75601
- Research Site
-
San Antonio, Texas, Соединенные Штаты, 78240
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84106
- Research Site
-
-
Virginia
-
Midlothian, Virginia, Соединенные Штаты, 23114
- Research Site
-
Norfolk, Virginia, Соединенные Штаты, 23502
- Research Site
-
-
Washington
-
Tacoma, Washington, Соединенные Штаты, 98405
- Research Site
-
-
Wisconsin
-
Waukesha, Wisconsin, Соединенные Штаты, 53226
- Research Site
-
-
-
-
-
Kaohsiung City, Тайвань, 833
- Research Site
-
Taichung, Тайвань, 40705
- Research Site
-
Tainan, Тайвань, 70403
- Research Site
-
Tainan, Тайвань, 710
- Research Site
-
Taipei, Тайвань, 100
- Research Site
-
Taipei, Тайвань
- Research Site
-
Taipei, Тайвань, 11490
- Research Site
-
Taipei, Тайвань, 23561
- Research Site
-
Taipei, Тайвань, 11259
- Research Site
-
Taipei, Тайвань, 110
- Research Site
-
Taoyuan, Тайвань, 333
- Research Site
-
-
-
-
-
Adana, Турция (Туркие), 01120
- Research Site
-
Ankara, Турция (Туркие), 06100
- Research Site
-
Ankara, Турция (Туркие), 06520
- Research Site
-
Ankara, Турция (Туркие), 06010
- Research Site
-
Ankara, Турция (Туркие), 06340
- Research Site
-
Cordaleo, Турция (Туркие), 35575
- Research Site
-
Izmir, Турция (Туркие), 35100
- Research Site
-
Izmir, Турция (Туркие), 35360
- Research Site
-
Kadıkoy/Istanbul, Турция (Туркие), 34722
- Research Site
-
Kayseri, Турция (Туркие), 38039
- Research Site
-
-
-
-
-
Avignon, Франция, 84918
- Research Site
-
Brest, Франция, 29200
- Research Site
-
Clermont-Ferrand, Франция, 63050
- Research Site
-
Dijon, Франция, 21079
- Research Site
-
Limoges, Франция, 83000
- Research Site
-
Lorient, Франция, 56322
- Research Site
-
Lyon, Франция, 69373
- Research Site
-
Marseille, Франция, 13273
- Research Site
-
Metz-Tessy, Франция, 74370
- Research Site
-
Nîmes, Франция, 30029
- Research Site
-
Paris, Франция, 75248
- Research Site
-
Rouen, Франция, 76021
- Research Site
-
Saint-Cloud, Франция, 92210
- Research Site
-
Saint-Herblain, Франция, 44805
- Research Site
-
Toulouse, Франция, 31100
- Research Site
-
Tours, Франция, 37000
- Research Site
-
Vandœuvre-lès-Nancy, Франция, 54519
- Research Site
-
Vantoux, Франция, 57070
- Research Site
-
Villejuif, Франция, 94805
- Research Site
-
-
-
-
-
Bern, Швейцария, CH-3010
- Research Site
-
Chur, Швейцария, CH-7000
- Research Site
-
Winterthur, Швейцария, 8401
- Research Site
-
-
-
-
-
Cheonan-si, Южная Корея, 31151
- Research Site
-
Daegu, Южная Корея, 42415
- Research Site
-
Goyang-si, Южная Корея, 10408
- Research Site
-
Seongnam-si, Южная Корея, 13620
- Research Site
-
Seongnam-si, Южная Корея, 463-712
- Research Site
-
Seoul, Южная Корея, 02841
- Research Site
-
Seoul, Южная Корея, 03080
- Research Site
-
Seoul, Южная Корея, 03722
- Research Site
-
Seoul, Южная Корея, 05505
- Research Site
-
Seoul, Южная Корея, 06273
- Research Site
-
Seoul, Южная Корея, 06351
- Research Site
-
Seoul, Южная Корея, 06591
- Research Site
-
-
-
-
-
Chiba, Япония, 260-8717
- Research Site
-
Chūōku, Япония, 104-0045
- Research Site
-
Hidaka-shi, Япония, 350-1298
- Research Site
-
Hirakata-shi, Япония, 573-1191
- Research Site
-
Kitaadachi-gun, Япония, 362-0806
- Research Site
-
Kumamoto, Япония, 860-8556
- Research Site
-
Kōtoku, Япония, 135-8550
- Research Site
-
Matsuyama, Япония, 791-0280
- Research Site
-
Nagoya, Япония, 464-8681
- Research Site
-
Nagoya, Япония, 467-8602
- Research Site
-
Niigata, Япония, 951-8566
- Research Site
-
Osaka, Япония, 540-0006
- Research Site
-
Osaka, Япония, 541-8567
- Research Site
-
Ota-shi, Япония, 373-8550
- Research Site
-
Sapporo, Япония, 003-0804
- Research Site
-
Shinagawa-ku, Япония, 142-8666
- Research Site
-
Shinjuku-ku, Япония, 162-8655
- Research Site
-
Takasaki-shi, Япония, 370-0829
- Research Site
-
Takatsuki-shi, Япония, 569-8686
- Research Site
-
Tsukuba, Япония, 305-8577
- Research Site
-
Yokohama, Япония, 241-8515
- Research Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
INCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:
- Have advanced breast cancer that is not able to be treated with surgery or radiation;
- Have an ESR1 mutation in their cancer;
- Have breast cancer that is HR-positive and HER2-negative;
- Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
- Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
- Are able to do their daily activities;
- Are at least 18.
Full list of inclusion criteria:
- Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent;
- Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
- Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
- Eastern Cooperative Oncology Group performance status of 0 or 1;
- ESR1m detected by central testing of ctDNA with Guardant360® CDx;
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
- Adequate organ and marrow function.
EXCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:
- Had certain types of tumors in the past that may come back;
- Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
- Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.
Full list of exclusion criteria:
- Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
- Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease;
- Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
- Patient with known or family history of severe heart disease;
- Previous treatment with AZD9833, investigational SERDs or fulvestrant;
- Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
- Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: AZD9833 + palbociclib, abemaciclib or ribociclib
The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily) |
Dosage formulation: AZD9833 tablets will be administered orally Dosage formulation: anastrozole placebo tablets will be administrated orally. Dosage formulation: letrozole placebo tablets will be administered orally. Dosage formulation: palbociclib tablets/capsules will be administered orally Dosage formulation: abemaciclib tablets will be administered orally Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist. Dosage formulation: ribociclib tablets will be administered orally |
|
Активный компаратор: Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib
The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily) |
Dosage formulation: palbociclib tablets/capsules will be administered orally Dosage formulation: abemaciclib tablets will be administered orally Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist. Dosage formulation: ribociclib tablets will be administered orally Dosage formulation: AZD9833 placebo tablets will be administrated orally. Dosage formulation: anastrozole tablets will be administered orally. Dosage formulation: letrozole tablets will be administered orally. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)
Временное ограничение: From randomization until the earlier of the progression event or death (approximately 2 years)
|
PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death. |
From randomization until the earlier of the progression event or death (approximately 2 years)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free survival 2 (PFS2)
Временное ограничение: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
|
PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death. |
From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
|
|
Overall survival (OS)
Временное ограничение: From randomization until the date of death due to any cause (approximately 5 years)
|
The OS is defined as the time from randomization to death due to any cause. |
From randomization until the date of death due to any cause (approximately 5 years)
|
|
Chemotherapy free survival
Временное ограничение: From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
|
Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause. |
From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
|
|
Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1
Временное ограничение: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
|
ORR is defined as the proportion of patients who have a complete response (CR) or partial response (PR), as determined by the investigator at local site per RECIST 1.1. |
From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
|
|
Clinical benefit rate at 24 weeks (CBR24)
Временное ограничение: At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
|
CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for At least 23 weeks after randomisation for each patient to allow for an early assessment within the assessment window (1 week window for RECIST assessment) |
At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
|
|
Change from baseline in EORTC QLQ-C30 scale scores
Временное ограничение: From baseline until second progression (approximately 5 years)
|
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden. |
From baseline until second progression (approximately 5 years)
|
|
Change from baseline in EORTC QLQ-BR23 scale scores
Временное ограничение: From baseline until second progression (approximately 5 years)
|
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden. |
From baseline until second progression (approximately 5 years)
|
|
Plasma concentration of AZD9833 at specified timepoints
Временное ограничение: on Day 15 for each patient
|
To assess the steady state PK of AZD9833 in combination with palbociclib or abemaciclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration. |
on Day 15 for each patient
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Общие публикации
- Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056/NEJMoa2502929. Epub 2025 Jun 1.
- Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18.
- Brufsky A, Park YH, Bidard FC, Mayer EL, Janni W, Ma C, Cristofanilli M, Bianchini G, Iwata H, Fasching PA, Nowecki Z, Pascual J, Chen SC, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Jung KH, Kikawa Y, Baird RD, Habash R, Sugarman R, Fox S, Selvi Miralles M, Huang Bartlett C, Turner N. SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy. Oncologist. 2026 Aug 6;31(9):oyag278. doi: 10.1093/oncolo/oyag278.
- Turner NC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Brufsky AM, Fasching PA, Nowecki Z, Pascual J, Karadurmus N, Gal-Yam E, Chung WP, Im SA, Zambelli A, Dalenc F, Oliveira M, Ishiguro H, Huang CS, Klinowska T, Fox S, Morrow C, Robert L, Huang-Bartlett C, Bidard FC. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2026 Aug;27(8):941-958. doi: 10.1016/S1470-2045(26)00287-1. Epub 2026 Jul 13.
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
- Новообразования
- Двойной слепой
- Фаза III
- Метастатический
- Рибоциклиб
- Противоопухолевые агенты
- Новообразования молочной железы
- Физиологические эффекты лекарств
- Рандомизированный
- Эндокринная терапия
- Летрозол
- Палбоциклиб
- Новообразования по локализации
- Заболевания груди
- Абемациклиб
- Анастрозол
- Мультицентр
- AZD9833
- Оральный SERD следующего поколения
- Антагонисты
- Антагонисты рецепторов эстрогена
- Антагонисты гормонов
- камизетрант
- ESR1м
- Переключить лечение
- Эндокринная резистентность
Дополнительные соответствующие термины MeSH
- Патологические процессы
- Неопластические процессы
- Кожные заболевания
- Патологические состояния, признаки и симптомы
- Заболевания кожи и соединительной ткани
- Новообразования
- Новообразования молочной железы
- Метастаз новообразования
- Заболевания груди
- Новообразования по локализации
- Гормоны
- Гормоны, заменители гормонов и антагонисты гормонов
- Гормоны гормонов гипофиза
- Гормоны гипоталамуса
- Пептидные гормоны
- Нейропептиды
- Пептиды
- Аминокислоты, пептиды и белки
- Олигопептиды
- Белки нервной ткани
- Белки
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Азолы
- Нитрилы
- Триазолы
- Летрозол
- Анастрозол
- Гонадотропин-рилизинг-гормон
- abemaciclib
- рибоциклиб
- palbociclib
- AZD9833
Другие идентификационные номера исследования
- D8534C00001
- 2023-503990-39-00 (Другой идентификатор: EU CT number)
- 2021-000546-17 (Номер EudraCT)
- 2023 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Сроки обмена IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Критерии совместного доступа к IPD
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .